Page 1 | Search Results | Blood Advances | American Society of Hematology

1-5 of 5

Sort by

Sort Order Select

Journal Articles

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

Kenki Saito, Kazuya Sakai, Masayuki Kubo, Hidekazu Azumi, Atsushi Hamamura, Shinichi Ochi, Hiroki Amagase, Hisako Kunieda, Yoshiyuki Ogawa, Hideo Yagi, Masanori Matsumoto

Blood Adv (2024) 8 (9): 2151–2159.

https://doi.org/10.1182/bloodadvances.2023012451

Published: 2024

Includes: Supplemental data

Journal Articles

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

Kazuya Sakai, Masanori Matsumoto, Laure De Waele, Charlotte Dekimpe, Eriko Hamada, Masayuki Kubo, Claudia Tersteeg, Simon F. De Meyer, Karen Vanhoorelbeke

Blood Adv (2023) 7 (1): 131–140.

https://doi.org/10.1182/bloodadvances.2022008885

Published: 2023

Includes: Supplemental data

Journal Articles

First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative

Hiroshi Azuma, Toraji Amano, Naoya Kamiyama, Naofumi Takehara, Maki Jingu, Harumi Takagi, Osamu Sugita, Naoko Kobayashi, Tomoko Kure, Taro Shimizu, Tatsuhiro Ishida, Masanori Matsumoto, Hiromi Sakai

Blood Adv (2022) 6 (21): 5711–5715.

https://doi.org/10.1182/bloodadvances.2022007977

Published: 2022

Includes: Supplemental data

Journal Articles

Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome

Yoshihiro Fujimura, Bernhard Lämmle, Saori Tanabe, Kazuya Sakai, Toshiyuki Kimura, Koichi Kokame, Toshiyuki Miyata, Yukihiro Takahashi, Shigeki Taniguchi, Masanori Matsumoto

Blood Adv (2019) 3 (21): 3191–3195.

https://doi.org/10.1182/bloodadvances.2019000601

Published: 2019

Journal Articles

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

Yoko Yoshida, Masanori Matsumoto, Hideo Yagi, Ayami Isonishi, Kazuya Sakai, Masaki Hayakawa, Yuji Hori, Toshiyuki Sado, Hiroshi Kobayashi, Yoshihiro Fujimura

Blood Adv (2017) 1 (20): 1628–1631.

https://doi.org/10.1182/bloodadvances.2017006767

Published: 2017

Includes: Supplemental data

NARROW

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative

Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

Email alerts

ASH Publications

American Society of Hematology

Persistent ADAMTS13 inhibitor delays recovery of ADAMTS13 activity in caplacizumab-treated Japanese patients with iTTP

ADAMTS13 conformation and immunoprofiles in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura

First-in-human phase 1 trial of hemoglobin vesicles as artificial red blood cells developed for use as a transfusion alternative

Patent ductus arteriosus generates neonatal hemolytic jaundice with thrombocytopenia in Upshaw-Schulman syndrome

Severe reduction of free-form ADAMTS13, unbound to von Willebrand factor, in plasma of patients with HELLP syndrome

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only